In looking at the company's intent to partner it's
Post# of 15624
(Total Views: 330)
Posted On: 07/23/2017 3:56:59 PM
In looking at the company's intent to partner it's products, I would like to hear others opinions on whether the Mediq agreement constitute's such a partnership.
I personally haven't viewed Mediq as providing the same sort of resources to OWCP that a partnership with a big Pharma company would, but perhaps I'm wrong about Mediq's capability in Germany, or perhaps throughout Europe.
I've seen where others who spoke with Mediq believe they're undertaking new trials demonstrating the efficacy of the cream. If in reality, Mediq is financing these trials, I have underestimated their responsibility and capability.
I believe some clarification is needed from OWCP, but history has shown they don't really care to define such things that clearly. Most of their language would have us thinking they are a biotech that happens to use cannabis, however, in saying the cream is market ready, I think investors view it as being able to be marketed without full drug approval in places where such sales are permitted.
The next quarterly report is due in roughly the next three weeks. I would hope the quarterly clears up some of the confusion and hopefully provides an outline for what's expected in the future.
Gary
I personally haven't viewed Mediq as providing the same sort of resources to OWCP that a partnership with a big Pharma company would, but perhaps I'm wrong about Mediq's capability in Germany, or perhaps throughout Europe.
I've seen where others who spoke with Mediq believe they're undertaking new trials demonstrating the efficacy of the cream. If in reality, Mediq is financing these trials, I have underestimated their responsibility and capability.
I believe some clarification is needed from OWCP, but history has shown they don't really care to define such things that clearly. Most of their language would have us thinking they are a biotech that happens to use cannabis, however, in saying the cream is market ready, I think investors view it as being able to be marketed without full drug approval in places where such sales are permitted.
The next quarterly report is due in roughly the next three weeks. I would hope the quarterly clears up some of the confusion and hopefully provides an outline for what's expected in the future.
Gary
(2)
(0)